Alza Corporation

Durect Corporation

Other

Virginia Commonwealth University

Microlin, LLC

Microlin, L.c.

The United States Government As Represented by the Department of Veterans Affairs

Felix T Theeuwes

Patrick S Wong

Ronald P Haak

John Urquhart

J Richard Gyory

James B Eckenhoff

Su Il Yum

Atul D Ayer

Joseph C Deters

Richard Lewis Cortese

Brian L Barclay

George V Guittard

Steven D Larsen

Alejandro C Zaffaroni

David E Edgren

J Bradley Phipps

Paul R Magruder

Gary A Lattin

Hoa T Huynh

Jeremy C Wright

Michel J N Cormier

Alan S Michaels

Suneel K Gupta

James E Brown

Liang C Dong

Eun Soo Lee

Nathan Roth

Robert M Myers

Felix A Landrau

Anthony L Kuczynski

John W Gibson

Edward M Gillis

Patrick S-l Wong

Shunlin Ren

Keith Edward Branham

WeiQi Lin

Patrick J Lew

Lyn C Moodie

Randolph Mellus Johnson

Ashok V Joshi

Armand P Neukermans

Sai Bhavaraju

Francisco Jao

Liang-Chang Dong

Michael H Dealey

Strahinja K Zecevic

Pieter Bonsen

James Matriano

Phyllis I Gardner

William W Van Osdol

Michael M Sekar

David K Roe

Bonnie Burdett Dennis, Legal Representative

James M Davenport

Allan M Wolfe

Jason J Wan

Whitney Moro

John Tipton

Robert M Gale

Andrew I Poutiatine

Barry Block

Alfred A Amkraut

Vincent Joseph Ferrari

Patrick S L Wong

David R Swanson

Irving K Arenberg

Richard J Saunders

Michael H Arenberg

James A Filice

Stefania Sjobeck

Wei-Qi Lin

Scott A Bura

Barbara F Laidlaw

Peter Wickman

John Culwell

John S Dinka

Nalinkant C Damani

Joseph G Luschen

Dana Litmanovitz

Christine Lemke

John A Berglund

Su Ii Yum

Timothy Scott Nelson

Stahinja K Zecevic

Patrick Wong S L

Wayne S Mefford

William F Bayne

Kevin J Mullins

Mark DuBois

Joseph C Oeters

J Benjamin Eckenhoff

Bonnie Burdett Dennis

Deters, Joseph C

Marc L Bartoo

Su-Il Yum

Ben Eckenhoff

Jeremy Corwin Wright

Weiqi Lin

Keith E Branham

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

Uses of oxygenated cholesterol sulfates (OCS)

The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.

Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37&#xb0; C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.

Depot formulations

Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.

Transdermal delivery system for sufentanil

Transdermal delivery systems

A method of increasing the delivery efficiency of an agent through a body surface by electrotransport is disclosed wherein the electrotransport current is applied for durations at a higher current density values followed by durations of lower current density values wherein the higher current density applications transform the body surface to an enhanced, non-transitory agent delivery efficiency state.

Electrotransport agent delivery method and apparatus

A fluid delivery device, comprising an electrochemical pump, wherein the pump is capable of transporting water; a pump product chamber, wherein the pump product chamber is capable of retaining water generated from the pump; a displaceable member positioned between the pump product chamber and a reservoir, wherein the displaceable member is controllably displaced upon generation of water from the electrochemical pump; a reservoir, wherein the reservoir is capable of containing a fluid which is delivered upon displacement of the displaceable member; and an housing for containing the pump, the pump product chamber, the displaceable member, and the reservoir.

Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method

The present invention is directed to an apparatus and method for controllably adjusting a fluid delivery device. The device includes an electrochemical pump capable of transporting a fluid. A displaceable member is positioned between a pump product chamber and a reservoir, wherein the pump product chamber is capable of retaining water generated from the pump. The displaceable member is controllably displaced upon generation of water from the electrochemical pump and the reservoir contains the fluid that is delivered upon displacement of the displaceable member.

Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method

The invention provides a local concentration management system (LCMS) for delivery of highly concentrated therapeutic agent formulations. The LCMS comprises a device comprising an elongate body defining a lumen between its proximal and distal ends, and a diffuser element, a dilutor element, or both. The diffuser element, which is selectively permeable to the agent, is operatively associated with the elongate body so that agent flows through the elongate body, and into and through the diffuser element to exit the system. The dilutor element can be operatively associated with the system to be in fluid communication with the elongate body lumen, a diffusion space defined by a diffuser element inner wall, or both. The dilutor element is selectively water permeable, but substantially impermeable to agent, to provide for dilution of the agent during transit through the system. The LCMS system is designed to disperse and/or dilute the drug delivery stream.

Local concentration management system

The present invention is disclosed herein as an electrochemical cell having a cell housing with a first half cell and a second half cell, and an ion selective membrane between the cells. The electrochemical cell further has a first electrode positioned within the first half cell, a second electrode positioned within the second half cell, an electrolyte in electrical communication with both the first electrode and the second electrode. The electrodes of the cell are configured so that the electrochemical cell maintains a substantially constant salt concentration level throughout operation. The cell is preferably used in conjunction with an implantable fluid delivery apparatus. A method for using the device is additionally disclosed.

Dual electrode advanced electrochemical delivery system

An osmotic delivery system having a space-efficient piston is provided. The enclosure has an interior holding the piston, a protein or peptide, and an osmotic agent. The piston is movable with respect to an interior surface of the capsule, and defines a movable seal with the interior surface of the capsule. The movable seal separates the osmopolymer from the protein or peptide. The piston has a recess that receives at least a portion of the osmotic agent. The osmotic agent imbibes liquid from a surrounding environment to cause the piston to move and, in turn, cause delivery of the beneficial agent from the capsule.

Osmotic delivery system having space-efficient piston

Growing community of inventors

Los Altos Hills, CA, United States of America

Felix T Theeuwes